238 related articles for article (PubMed ID: 17110336)
41. Generation and Characterization of Site-Specifically Mono-Ubiquitylated p53.
Julier A; Radtke V; Marx A; Scheffner M
Chembiochem; 2022 Mar; 23(6):e202100659. PubMed ID: 35025136
[TBL] [Abstract][Full Text] [Related]
42. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Watts GS; Oshiro MM; Junk DJ; Wozniak RJ; Watterson S; Domann FE; Futscher BW
Neoplasia; 2004; 6(3):187-94. PubMed ID: 15153330
[TBL] [Abstract][Full Text] [Related]
43. Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.
Ding Y; Lee JF; Lu H; Lee MH; Yan DH
Mol Cell Biol; 2006 Mar; 26(5):1979-96. PubMed ID: 16479015
[TBL] [Abstract][Full Text] [Related]
44. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation.
Hebner C; Beglin M; Laimins LA
J Virol; 2007 Dec; 81(23):12740-7. PubMed ID: 17898049
[TBL] [Abstract][Full Text] [Related]
45. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination.
Lee MH; Lee SW; Lee EJ; Choi SJ; Chung SS; Lee JI; Cho JM; Seol JH; Baek SH; Kim KI; Chiba T; Tanaka K; Bang OS; Chung CH
Nat Cell Biol; 2006 Dec; 8(12):1424-31. PubMed ID: 17086174
[TBL] [Abstract][Full Text] [Related]
46. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
47. Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein and ubiquitin ligase MDM2.
Liu J; Zou X; Gotoh T; Brown AM; Jiang L; Wisdom EL; Kim JK; Finkielstein CV
Sci Signal; 2018 Nov; 11(556):. PubMed ID: 30425162
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
49. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
[TBL] [Abstract][Full Text] [Related]
50. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
[TBL] [Abstract][Full Text] [Related]
51. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
52. The multifunctional protein E4F1 links P53 to lipid metabolism in adipocytes.
Lacroix M; Linares LK; Rueda-Rincon N; Bloch K; Di Michele M; De Blasio C; Fau C; Gayte L; Blanchet E; Mairal A; Derua R; Cardona F; Beuzelin D; Annicotte JS; Pirot N; Torro A; Tinahones FJ; Bernex F; Bertrand-Michel J; Langin D; Fajas L; Swinnen JV; Le Cam L
Nat Commun; 2021 Dec; 12(1):7037. PubMed ID: 34857760
[TBL] [Abstract][Full Text] [Related]
53. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
[TBL] [Abstract][Full Text] [Related]
54. PCAF modulates PTEN activity.
Okumura K; Mendoza M; Bachoo RM; DePinho RA; Cavenee WK; Furnari FB
J Biol Chem; 2006 Sep; 281(36):26562-8. PubMed ID: 16829519
[TBL] [Abstract][Full Text] [Related]
55. CDK8 is a stimulus-specific positive coregulator of p53 target genes.
Donner AJ; Szostek S; Hoover JM; Espinosa JM
Mol Cell; 2007 Jul; 27(1):121-33. PubMed ID: 17612495
[TBL] [Abstract][Full Text] [Related]
56. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
57. P53 mRNA controls p53 activity by managing Mdm2 functions.
Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
[TBL] [Abstract][Full Text] [Related]
58. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Shiseki M; Nagashima M; Pedeux RM; Kitahama-Shiseki M; Miura K; Okamura S; Onogi H; Higashimoto Y; Appella E; Yokota J; Harris CC
Cancer Res; 2003 May; 63(10):2373-8. PubMed ID: 12750254
[TBL] [Abstract][Full Text] [Related]
59. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity.
Bordoli L; Hüsser S; Lüthi U; Netsch M; Osmani H; Eckner R
Nucleic Acids Res; 2001 Nov; 29(21):4462-71. PubMed ID: 11691934
[TBL] [Abstract][Full Text] [Related]
60. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
